Table 5 Comparison of effect of fluticasone and “other ICS” on outcomes
From: Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis
Outcome | Multivariate hazard ratio | ||
|---|---|---|---|
(95% CI) | |||
No ICS | Other ICS | Fluticasone | |
Primary endpoints | |||
New case diabetes | 1.00 | 0.98 (0.69-1.39) | 0.82 (0.58-1.15) |
Worsening of existing diabetes | 1.00 | 1.01 (0.72-1.41) | 0.84 (0.60-1.17) |
Secondary endpoints | |||
Hospitalisation for pneumonia | |||
No carryover | 1.00 | 0.88 (0.68-1.14) | 1.23 (1.01-1.51) |
180-day carryover | 1.00 | 1.05 (0.79-1.39) | 1.50 (1.17-1.91) |
Hospitalisation for fracture | 1.00 | 1.08 (0.72-1.60) | 1.10 (0.57-2.10) |
Cataract related outcome | 1.00 | 1.34 (0.99-1.82) | 2.24 (1.40-3.60) |